Gain Therapeutics announced presentations, including two late-breakers, at Neuroscience 2024 featuring preclinical data supporting development of GT-02287, the Company’s clinical stage lead drug candidate, in Parkinson’s disease with or without a GBA1 mutation. Neuroscience 2024, the Society for Neuroscience’s premier event, will be held at McCormick Place Convention Center in Chicago, IL from October 5-9, 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GANX:
- Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson’s Disease Models Including Two Late-Breakers at Neuroscience 2024
- Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease
- Gain Therapeutics announces reuslts from Phase 1 study of GT-02287
- Gain Therapeutics assumed with an Outperform at Oppenheimer
- Gain Therapeutics reports Q2 EPS (42c), consensus (20c)